drugset / Trial / NCT01251835

Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan

NCT01251835

Phase 1 Withdrawn Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

This study will assess how rifampin will affect the blood levels of sitaxsentan. Safety of sitaxsentan given alone and with rifampin will also be assessed.

Timeline

Start
2010-12
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifampin Small molecule 600 mg
Subject Sitaxentan Small molecule 100 mg